Comparison of the effectiveness and safety between gabapentin and amitriptyline in pain improvement in peripheral diabetic neuropathy patients: a review

  • Nindita Rachmania Master of Clinical Pharmacy Program, Faculty of Pharmacy, Universitas Gadjah Mada Yogyakarta
  • Probosuseno Departement of Internal Medicine, Universitas Gadjah Mada Yogyakarta
  • Fita Rahmawati 3Departement of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada Yogyakarta
Keywords: neuropathy diabetic, pain, gabapentin, amitriptyline, effectiveness


Neuropathy pain is one chronic pain that is difficult to treat and has not had an ideal curative therapy, yet. Gabapentin and amitriptyline are widely used as diabetic neuropathy therapies. However, their effectiveness is still debatable and their side effect has been reported. Several factors affect the efficacy and morbidity of gabapentin and amitriptyline in diabetic neuropathy patients. Some treatment options for diabetic neuropathy are available in clinical setting, therefore evaluation the effectiveness of the treatment options is needed to choose the best treatment. This review article evaluated the effectiveness and safety between gabapentin and amitriptyline as pain relief in peripheral diabetic neuropathy (PDN) patients. It was a narrative review using electronic databases such as Science Direct, Scopus and PubMed. The results showed that effectiveness and safety of gabapentin is better than amitriptyline in relief pain on PDN.


Soelistijo SA, Suastika K, Lindarto D, Decroli E, Permana H, Sucipto KW, et al. Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di Indonesia 2021. Jakarta: PB Perkumpulan Endokrinologi Indonesia, 2021.

American Diabetes Care Association. Microvascular complications and foot care: standards of medical care in diabetes 2021. Diabetes Care 2021; 44 (Suppl. 1):S151–67.

Kuate-Tegueu C, Temfack E, Ngankou S, Doumbe J, Djientcheu VP, Kengne AP. Prevalence and determinants of diabetic polyneuropathy in a sub-Saharan African referral hospital. J Neurol Sci 2015;355(1-2):108-12.

Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, et al. American Association of Clinical Endocrinologists and American College of Endocrinology : clinical practice guidelines for developing a diabetes mellitus comprehensive care plan 2015. Endocr Pract 2015; 21 Suppl 1(Suppl 1):1-87.

https://doi: 10.4158/EP15672.

Mancini GBJ, Hegele RA, Leiter LA. Dyslipidemia - diabetes Canada clinical practice guidelines expert committee. Can J Diabetes 2018;42:S178-85.

Jaya MKA, Kuswardhani RAT. Safety comparison between amitriptyline versus gabapentin on neuropathic pain therapy in geriatric with type II diabetes mellitus. Bali Med J 2016;5(3):129.

Chandra M, Garg R, Kaur J, Santram, Kaur N, Pal R. Evaluation of efficacy of amitriptyline vs gabapentin in diabetic peripheral neuropathy. Al Ameen J Med Sci 2017;10(3):194-200.

Sekar P, Punnagai K, David DC. Comparative study of safety and efficacy of gabapentin versus amitriptyline in patients with painful diabetic peripheral neuropathy, a randomized open label parallel group study. Biomed Pharmacol J 2017;10(3):1259-65.

Jaya MKA, Herawati F. Effectivity comparison of amitriptyline versus gabapentin as neurophatic pain therapy in elderly with type ii diabetes mellitus. Int J Curr Res 2017; 9(01):44769-73.

Liampas A, Rekatsina M, Vadalouca A, Paladini A, Varrassi G, Zis P. Pharmacological management of painful peripheral neuropathies: a systematic review. Pain Ther 2021;10(1):55-68.

Price R, Smith D, Franklin G, Gronseth G, Pignone M, David WS, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN guideline subcommittee. Neurology 2022; 98(1):31-43.

Jetli S, Verma A, Sharma H. A comparative study on efficacy and safety for management of neuropathic pain with gabapentin, pregabalin, and amitriptyline. Pakistan J Med Heal Sci 2021;15(9):2995-8.

Kaur R, Sehgal VK, Sibia RPS, Kaur A, Kumar A. Comparative analysis of efficacy and safety of gabapentin vs amitriptyline in patients of peripheral neuropathic pain in case of diabetes mellitus. Int J Med Dent Sci 2019;8(2):1775-82.

Shaikh H, Syed MH, Khan IN, Mubeen F. Comparative study of safety and efficacy of pregabalin and gabapentin in management of neuropathic pain associated with chronic lumbar radiculopathy. Int J Basic Clin Pharmacol 2019; 8(11):2480.

Alharbi A. comparative study to evaluate efficacy and safety for management of neuropathic pain with gabapentin, pregabalin, and amitriptyline. Pakistan J Med Heal Sci 2021;15(9):2995-8.

Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17(9):1113-e88.

Bril V, England JD, Franklin GM, Backonja M, Cohen JA, del Toro DR, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy-report of the American association of neuromuscular and electrodiagnostic medicine, the American academy of neurology, and the American academy of physical medicine & rehabilitation. Muscle and Nerve 2011;43(6):910-7.

Chincholkar M. Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice. Br J Pain 2020;14(2):104-14.

Su M. Amitriptyline therapy in chronic pain. Int Arch Clin Pharmacol 2015;1(1):1-5.

Buvanendran A, Kroin JS, Kari M, Tuman KJ. Can a single dose of 300 mg of pregabalin reach acute antihyperalgesic levels in the central nervous system? Reg Anesth Pain Med 2010;35(6):535-8.

Thour A, Marwaha R. Amitriptyline. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.

Gupta SK, Shah JC, Hwang SS. Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline. Br J Clin Pharmacol 1999; 48(1):71-8. 10.1046/j.1365-2125.1999.00973.x.